Propanc Biopharma, Inc. (Nasdaq: PPCB) announced that it and its research partners at the Universities of Jaén and Granada have published new findings in the open‑access journal Scientific Reports. The study, titled “Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts,” demonstrates that the company’s lead candidate, PRP, can disrupt the tumor microenvironment by targeting cancer‑associated fibroblasts in pancreatic ductal adenocarcinoma (PDAC).
The research shows that PRP, a formulation of bovine‑derived trypsinogen and chymotrypsinogen, exerts multifaceted effects on PDAC fibroblasts and tumor cells, suggesting it could serve as an adjunct therapy for patients who no longer respond to standard treatments. The publication marks a key preclinical milestone that underpins the company’s plan to initiate a Phase 1b study in advanced solid‑tumor patients in Q3 2026.
Propanc remains a development‑stage company with no revenue and consistent net losses. In Q2 2025 the company reported a net loss of $0.430 million, and for the six months ended December 31 2024 the loss was $0.784 million. The company’s market capitalization is approximately $9.5 million, and it relies on financing activities to fund its operations.
CEO James Nathanielsz said the results “highlight PRP as a promising adjunct therapeutic candidate capable of disrupting key interactions within the PDAC tumor microenvironment.” He added that the findings “demonstrate PRP’s potential to dramatically alter the treatment landscape for patients with this aggressive disease.”
The company plans to launch a Phase 1b trial in advanced solid‑tumor patients in Q3 2026, building on the preclinical data and the company’s ongoing patent filings. The trial will evaluate safety, tolerability, and preliminary efficacy of PRP in a first‑in‑human setting.
The publication follows a series of R&D milestones that have attracted investor attention, including recent patent filings and the announcement of the Phase 1b trial plan. While the company continues to face headwinds such as ongoing financing needs and the inherent risks of drug development, the scientific validation provided by the Scientific Reports study strengthens its clinical development narrative and positions PRP as a potential breakthrough in a high‑unmet‑need area of oncology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.